Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations.
In Europe, azacitidine is the only hypomethylating agent approved for the treatment of patients with int-2-/high-risk myelodysplastic syndromes, offering significantly improved survival compared with conventional care. However, not all patients treated with azacitidine respond to treatment, and the...
| Hoofdauteurs: | , , , , , , , |
|---|---|
| Formaat: | Journal article |
| Taal: | English |
| Gepubliceerd in: |
Elsevier
2014
|